Purpose To investigate clinical implications of FDG uptake in the thyroid glands in patients with advanced breast carcinoma by comparing metabolic and morphologic patterns on positron emission tomography (PET)/computed tomography (CT). Methods The institutional review board waived the requirement for informed consent. A retrospective analysis was performed in 146 women (mean age 54 years) with advanced breast carcinoma who received systemic treatment. All patients underwent PET-CT before and after treatment. All PET-CT studies were reviewed in consensus by two reviewers. Morphologic changes including volume and mean parenchymal density of the thyroid glands were evaluated. Maximum standardized uptake value (SUVmax) and total lesion glycolysis (TLG) were determined to evaluate metabolic changes. These parameters were compared between patients with chronic thyroiditis who received thyroid hormone replacement therapy and those who did not. Results Of the 146 patients, 29 (20%) showed bilaterally diffuse uptake in the thyroid glands on the baseline PET-CT scan. The SUVmax showed a linear relationship with volume (r=0.428, p=0.021) and the mean parenchymal density (r=−0.385, p=0.039) of the thyroid glands. In 21 of the 29 patients (72%) with hypothyroidism who received thyroid hormone replacement therapy, the volume, mean parenchymal density, SUVmax, and TLG of the thyroid glands showed no significant changes. In contrast, 8 of the 29 patients (28%) who did not receive thyroid hormone replacement therapy showed marked decreases in SUVmax and TLG. Conclusion Diffuse thyroid uptake on PET-CT represents active inflammation caused by chronic thyroiditis in patients with advanced breast carcinoma. Diffuse thyroid uptake may also address the concern about subclinical hypothyroidism which develops into overt disease during follow-up.
uptake are seen in healthy subjects and oncology patients. A focal thyroid lesion with significant uptake is likely to be malignant [2] , whereas several benign conditions including nodular hyperplasia, nodular goiter, follicular tumor, and chronic thyroiditis also show high standardized uptake values (SUV) [1] [2] [3] [4] . This is a cause of significant overlap between malignant and benign lesions for differential diagnosis. Diffuse increased uptake in the thyroid glands favors several thyroidal disorders which include chronic thyroiditis, Graves' disease, diffuse goiter, and multinodular goiter [5] [6] [7] [8] [9] .
On the other hand, epidemiologic studies have shown a clinical correlation between thyroid disorders and the risk of invasive breast carcinoma. Patients with chronic thyroiditis have a higher incidence of breast carcinoma compared with patients who do not have thyroid disorders [10] [11] [12] [13] . The presence of serum antibody to thyroid peroxidase or clinical hypothyroidism [14] is associated with long overall survival in patients with invasive breast carcinoma. Overall, the results of previous studies suggest a clinical correlation between thyroid disorders and the risk of invasive breast carcinoma.
FDG PET is a well-established method to evaluate patients with breast carcinoma [15] [16] [17] [18] . Staging for lymph node metastases and distant metastases using FDG PET in addition to conventional imaging is effective in patients with advanced breast carcinoma who are clearly at a high risk at initial presentation. However, the clinical implications of diffuse thyroidal FDG uptake in chronic thyroiditis have not been clarified in patients with advanced breast carcinoma. In the present study, we retrospectively compared metabolic and morphologic patterns in chronic thyroiditis in patients with advanced breast carcinoma using PET-CT.
Materials and methods

Patients
A retrospective search of our institutional PET-CT database revealed 151 women who were referred for assessment of response of advanced breast carcinoma in a university hospital setting from June 2003 until August 2006. Only five patients had to be excluded from additional evaluation due to insufficient follow-up of less than 6 months. Thus the present analysis was based on 146 women (mean age 54 years, range 23-88 years). In detail, the primary tumors were unilateral in 139 patients (95%) and bilateral in 7 patients (5%). Initial staging showed stage IIIB in 22 patients (15%), stage IIIC in 22 patients (15%), and stage IV in 102 patients (70%). The preferred first-line treatments throughout the study period comprised chemotherapy, radiotherapy, and/or hormone therapy. Hormone therapy consisted of an estrogen-receptor (ER) antagonist (tamoxifen) or an aromatase inhibitor. Chemotherapy and radiotherapy was used to treat patients with widespread or life-threatening disease and ER-negative patients. Our institutional review board waived informed consent and approved the retrospective search in accordance with the Health Insurance Portability and Accountability Act.
Imaging studies
All imaging examinations were performed on an integrated PET-CT system (Discovery ST-8; GE Healthcare, Milwaukee, WI) with a whole-body mode implemented as the standard software. All patients except one underwent PET-CT before and after treatment. In one patient, only initial PET-CT was performed because of severe progression of disease. Sequential PET-CT was performed within 1 to 6 months after prior PET-CT. The patients fasted for at least 6 h before undergoing scanning. All patients were checked to confirm that their glucose level was within the normal range (average 5.43± 1.21 mmol/l) 4 h before scanning. The acquisition parameters for whole-body scans were axial 3.75-mm section thickness, 140 kVp, 120 mA, and a table feed of 13.5 mm per rotation. No oral or intravenous contrast agent was given to any of the patients. Emission scans of the PET study were obtained 81± 12 min after the intravenous injection of FDG (average dose 610.5 MBq, range 388.5-740.0 MBq) from the skull base to the upper thighs. The acquisition time was 3 min per bed position in the two-dimensional mode. PET images were iteratively reconstructed with attenuation correction based on a rescaling of the CT images. Emission data were corrected for scatter, random events, and dead-time losses using the manufacturer's software.
Image interpretation
All PET-CT studies were retrospectively reviewed in consensus by two reviewers. CT, PET, and the fused PET-CT images were read separately in consensus by two experienced investigators who were supplied with the same clinical information about each patient at a combined reading session. Images were reviewed at a dedicated workstation (Advantage Workstation; GE Healthcare). For the visual analysis, abnormal FDG uptake was defined as substantially greater activity than in the aortic blood on attenuation-corrected images. Metabolic activity within the thyroid glands was determined. A semiautomated tool was used to calculate the maximum SUV (SUVmax) within the volume of interest (VOI) according to the following equation: SUVmax = maximum measured activity within the VOI (MBq/ml)/injected dose of FDG (MBq)/body weight (g). The VOI was determined using a vendor-specific software tool that allowed automatic calculation of the SUVmax within a user-specific cubic volume drawn in three planes to include the site of abnormal accumulation. The total lesion glycolysis (TLG) was calculated as the product of the PET measurement based on the volume obtained by PET and the average SUV [19] .
CT findings were recorded for abnormalities including the heterogeneity of the thyroid parenchyma (homogeneous or heterogeneous) and the pattern of calcification (nodular, globular, amorphous, or linear) based on the CT portion of the PET-CT scan. When a space-occupying lesion was present, its exact size and the solid or cystic pattern were confirmed. The maximum diameter was measured in the axial plane for both lobes. The mean density (Hounsfield units) of the thyroid was obtained from a region of interest which was manually set on the CT portion of the PET-CT scan. The volume of each thyroid gland was calculated by the perimeter method [20] . The cross-sectional area of the thyroid glands was calculated by a workstation that manipulated a voxel matrix of 512×512 pixels. One board-certified radiologist who was experienced in using the image viewing and manipulation software drew a line around the perimeter of each thyroid twice. The total volume of the thyroid glands was calculated by summing the cross-sectional areas and multiplying by the section increment. The average values of the two volume calculations were used for the study analyses. PET-CT parameters including maximum diameter, volume, density, TLG, and SUVmax were compared to evaluate changes after thyroid hormone replacement therapy in patients with chronic thyroiditis.
Reference standard
Two board-certified radiologists retrospectively reviewed the medical records. All patients had clinical information for a follow-up of at least 6 months after PET-CT. We defined the standard of reference as clinical symptoms, findings on ultrasonography, serum measurements of free thyroxine (FT4; normal range 0.8-2.0 ng/dl), thyrotropin (TSH; normal range 0.45-4.5 mlU/l), antithyroglobulin antibody, antimicrosomal antibody, antiperoxidase antibody, and pathologic examinations using biopsy specimens obtained from fine needle biopsy or surgical biopsy. Diagnosis of chronic thyroiditis was verified pathologically in all patients with diffuse uptake on PET-CT. Clinical follow-up served as the standard reference according to a suggested approach to subclinical thyroid disease [21] . Patients were seen regularly for a minimum follow-up period of 6 months, if there was no evidence of progression of breast carcinoma. Clinical follow-up included all available clinical information, laboratory tests, ultrasound studies, and contrast-enhanced CT studies.
Statistical analysis
Continuous data are expressed as mean data throughout the article. Continuous variables were compared using Student's t test. Categorical variables were compared using the chisquared test or the Kruskal-Wallis test. Linear regression analysis was performed to express the relationship between morphologic and metabolic changes as determined by maximum diameter, volume, density, TLG, and SUVmax of the thyroid glands on PET-CT. In addition, we computed the correlation coefficients between morphologic and metabolic changes using Spearman's rank correlation test. A p value less than 0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed with the SPSS version 16 software program (SPSS, Chicago, IL).
Results
The clinical characteristics of the patients with or without bilaterally diffuse uptake in the thyroid glands on PET-CT are summarized in Table 1 . We identified 29 patients (20%) with bilaterally diffuse uptake in thyroid glands on PET-CT. The groups were well matched for age, weight, and numbers of sequential PET-CT examinations. After a median follow-up period of 23.5 months (range 7.6-59.8 months), 118 patients (80%) were alive with disease, and 28 patients (20%) had died of their disease. Among 29 patients with diffuse uptake, 10 (34%) had histologically proven chronic thyroiditis which showed typical features of Hashimoto's thyroiditis, 2 (7%) had chronic thyroiditis with multinodular goiter, and 17 (59%) had chronic thyroiditis which showed a lack of typical histologic findings of Hashimoto's thyroiditis. On the CT portion of the PET-CT scan, parenchymal homogeneity was not significantly different either in the patients with or in the patients without diffuse uptake (Table 2 ). However, patients with diffuse uptake had a much larger maximum diameter and volume on average than patients without diffuse uptake. Patients without diffuse uptake showed greater mean parenchymal density in the thyroid than patients with diffuse uptake. Space-occupying lesions in the parenchyma were identified in 53 patients (36%). Cystic lesions (n=31, 21%) were most frequent followed by calcification (n=16, 11%) and solid lesions (n=6, 4%). Three of six patients with a solid lesion had a pathologic diagnosis. Nodular hyperplasia was present in two patients and nodular goiter in one. Patients without diffuse uptake tended to have a space-occupying lesion in the parenchyma, but the frequency did not reach statistical significance. The pattern of calcification was classified as nodular in 12 patients (8%), globular in 2 patients (1%), amorphous in 1 patient (1%), and linear in 1 patient (1%).
On the baseline PET-CT scan, TLG as well as SUVmax of the thyroid glands were significantly higher in patients with diffuse uptake than in patients without diffuse uptake (p<0.0001, Table 3 ). When stratified by patients with diffuse uptake in the thyroid glands, the volume determined from the CT portion of the PET-CT scan showed a linear relationship with SUVmax (r=0.428, p=0.021, Fig. 1 ) and TLG (r=0.437, p=0.018). A similar relationship was noted for the mean parenchymal density and SUVmax (r=−0.385, p=0.039, Fig. 2 ). However, no significant correlation was seen between the mean parenchymal density and volume (r=−0.286, p=0.133) or TLG (r=−0.145, p=0.453) in patients with diffuse uptake in the thyroid glands. In contrast, when patients without diffuse uptake in the thyroid glands were included, there was no significant correlation between volume and SUVmax (r=0.086, p=0.355), volume and TLG (r=−0.001, p=0.991), and volume and the mean parenchymal density (r=−0.072, p=0.439). No significant correlation was seen between the mean parenchymal density and SUVmax (r=−0.049, p=0.603) or TLG (r=−0.001, p=0.991).
Of the 29 patients, 21 (72%) with diffuse uptake in the thyroid glands presented with symptoms of hypothyroidism (fatigue, lethargy, muscle stiffness, constipation, decreased libido, or depression). These patients received thyroid hormone replacement therapy. The median duration of follow-up was 23.7 months (range 19.0-31.0 months). All patients responded to thyroid hormone replacement therapy and recovered from fatigue or constipation. Sustained diffuse uptake in the thyroid glands was noted in these patients regardless of recovery from hypothyroidism (Fig. 3) . Of the 29 patients, 8 (28%) with diffuse uptake in the thyroid glands did not show any symptoms of hypothyroidism but manifested a slight elevation of serum TSH without elevation of serum thyroxine or triiodothyronine. These patients did not receive thyroid hormone replacement therapy. However, all patients developed symptoms of hypothyroidism during a median follow-up of 21.4 months (range 14.7-37.9). The follow-up PET-CT scan showed resolution of bilaterally diffuse uptake in the thyroid glands in these patients (Fig. 4) .
Comparing parameters between patients who received thyroid hormone replacement therapy and those who did not, the maximum diameter, volume, and mean parenchymal density of the thyroid glands evaluated on the CT portion of the PET-CT scan showed no significant changes (Table 4) . However, patients who did not receive thyroid hormone replacement therapy showed a marked decrease in TLG and SUVmax compared to patients who received thyroid hormone replacement therapy. Significant differences between patients with and without thyroid hormone replacement therapy were found in the changes in TLG and SUVmax from baseline (Table 4 ).
Discussion
Our survey of patients with advanced breast cancer identified diffuse thyroid uptake on PET-CT and is the first look in detail at the relationships between SUVmax, volume, and the mean parenchymal density of the thyroid. Diffuse thyroid uptake is incidentally identified in healthy subjects and patients with cancer on PET-CT and its incidence is 0.6-3.3% [5] [6] [7] [8] [9] . Compared to the results of previous studies, the prevalence of this condition in our study was considerably greater. This result is mirrored in the result of an initial study in which women with breast carcinoma had a high incidence of thyroid disorders [13, 14] .
Various causes of diffuse FDG uptake in the thyroid glands have been noted [5] [6] [7] [8] [9] . However, the precise mechanism for diffuse FDG uptake in the thyroid glands is unknown. Some investigators have reported that activated lymphocytes show enhanced glucose metabolism in chronic thyroiditis [7] . In contrast, the authors of one study with a large cohort of patients speculated that infiltration of fibroblasts resulted in continuous FDG uptake after treatment in patients with chronic thyroiditis [22] . Our study suggested that patients with advanced breast carcinoma who showed diffuse uptake in the thyroid glands on PET-CT might have had chronic thyroiditis. In our study, SUVmax was correlated with volume or the mean parenchymal density of the thyroid glands. This may be have been caused by the histological background. In chronic thyroiditis, lymphocytic infiltration results in enlargement of the thyroid glands and destruction of thyroid follicular cells causes a decrease in iodine content in the thyroid glands. Therefore, TLG, which is defined as average SUV multiplied by volume, might not show a significant correlation with the mean parenchymal density.
TLG is called the Larson-Ginsberg index, which was originally calculated using the volume obtained from PET and the average SUV [19] . TLG corresponds to the cell mass of the target lesion associated with FDG uptake. A change in TLG is a strong indicator of response to treatment in malignant tumors [23] . As expected, our data demonstrated that patients who did not receive thyroid hormone replacement therapy showed a marked decrease in TLG and SUVmax compared to patients who did receive thyroid hormone replacement therapy. TLG can also provide complementary information to that obtained by the more commonly used SUV.
The clinical diagnosis of hypothyroidism includes the presence of symptoms, elevation in serum TSH, decrease in serum free thyroxine, and decrease in serum free triiodothyronine. In most adult women hypothyroidism is the result of chronic thyroiditis [24] . Since the autoimmune process leads to cytotoxic conditions, death of thyroid follicular cells, and thyroid atrophy, there is a time lag from initial diagnosis of chronic thyroiditis until there is sufficient loss of thyroid follicular cells to cause hypothyroidism. In our study, 8 out of 29 patients with diffuse uptake in the thyroid glands had typical symptoms of hypothyroidism. In contrast, 21 patients with diffuse uptake in the thyroid glands showed a lack of symptom and normal serum free thyroxine and triiodothyronine levels, although the did show an elevation in serum TSH. Isolated elevation in serum TSH is defined as subclinical hypothyroidism [25] . Some investigators have suggested that thyroid hormone replacement therapy for patients with subclinical hypothyroidism would prevent symptoms of hypothyroidism [22] . However, the therapeutic benefits have not been established, and thus these patients were closely followedup in our study. The benefits of TSH follow-up for detecting subclinical hypothyroidism will be greater among individuals at high risk of developing overt disease, including advanced breast carcinoma. There are few studies in the literature addressing the relationship between chronic thyroiditis and hypothyroidism using PET. Karantanis et al. evaluated the relationship between SUVmax and the serum level of TSH in a retrospective analysis of 138 patients with diffuse thyroid uptake [22] . They noted that diffuse thyroid uptake might be associated with chronic thyroiditis, but no significant correlation between SUVmax and serum TSH level was found. These findings suggesting a possible association between FDG uptake and lymphocytic infiltration in the thyroid glands seem reasonable because most patients with chronic thyroiditis develop typical symptoms of hypothyroidism long after active inflammation.
It is unclear whether diffuse uptake in the thyroid glands changes after thyroid hormone replacement therapy. It is likely that continuous uptake in the thyroid glands would be found after a long-term follow-up without treatment. In our study, patients with diffuse uptake who received thyroid hormone replacement therapy showed lasting uptake. In contrast, patients who did not receive treatment showed a decrease in SUVmax, volume, and the mean parenchymal density on sequential PET-CT scans. After a prolonged follow-up without treatment, subclinical hypothyroidism will develop into overt disease, and severe atrophy of the thyroid glands, which will have a small volume and lower parenchymal density, may be observed. One criticism regarding the correlation of PET-CT measurements might be the inclusion of patients with active thyroiditis in whom clinical symptoms are limited as in subclinical hypothyroidism. If we include many patients with thyroid atrophy in the population, the relationship between SUVmax, volume, and the mean parenchymal density will differ from the results of the present study. Patients with thyroid atrophy will show lower SUVmax and lower mean parenchymal density on PET-CT. Thus, the presence of diffuse thyroid uptake on PET-CT appears to be a phenomenon in patients with active thyroiditis prior to the development of atrophy, whose symptom may be hypothyroidism or subclinical hypothyroidism. There are other potential limitations to the present study. Data were collected retrospectively, although the techniques for PET-CT measurements were used to minimize errors. The number of patients in the present study population was relatively small and the study might not have been sufficiently powered to explain the presence of subclinical hypothyroidism because the follow-up period in these patients might have been too short to detect symptoms of hypothyroidism. However, the primary outcome of the correlations in the PET-CT measurements in patients with diffuse thyroid uptake, as well as the finding of minimal changes in parameters after thyroid hormone replacement therapy, lend weight to our conclusions.
In summary, diffuse uptake in the thyroid glands on PET-CT represents the presence of inflammation caused by chronic thyroiditis in patients with advanced breast carcinoma. SUVmax had linear correlation with volume and the mean parenchymal density of the thyroid glands. Diffuse thyroid uptake lasted after thyroid hormone replacement therapy in patients who showed symptoms of hypothyroidism. Diffuse thyroid uptake may also address the concern about patients with subclinical hypothyroidism which develops into overt disease during follow-up.
